Literature DB >> 21605914

Suicidal ideation in Huntington disease: the role of comorbidity.

Heather H Wetzel1, Carissa R Gehl, Lisa Dellefave-Castillo, Judith F Schiffman, Kathleen M Shannon, Jane S Paulsen.   

Abstract

Huntington disease (HD) is a neurodegenerative condition characterized by cognitive impairments, motor abnormalities, and psychiatric disturbance. An increased risk for suicide has been documented. The majority of HD research has focused on cognitive and motor features of HD; the implications of psychiatric manifestations have received less consideration. Recent studies have sought to identify the stages of HD in which patients are at increased risk to experience suicidal ideation, though no study has examined possible risk factors for suicidality. The current study examines the presence of psychiatric comorbidity and its involvement in suicidal ideation. Suicidal ideation was examined in 1941 HD patients enrolled in the Huntington Study Group. Of those, 19% (N=369) endorsed current suicidal ideation. Logistic regression analyses indicated that depression/anxiety and aggression/irritability are significant predictors of suicidal ideation. In a subsample with the greatest suicidal ideation, alcohol and drug abuse were also predictive. It is recommended that all individuals with HD (specifically those with features of depression, aggression, substance abuse) have routine suicide assessment; further research is needed to understand the high rate of suicide in HD. 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21605914      PMCID: PMC3790459          DOI: 10.1016/j.psychres.2011.05.006

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  36 in total

1.  Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey.

Authors:  R C Kessler; G Borges; E E Walters
Journal:  Arch Gen Psychiatry       Date:  1999-07

2.  Suicide as an outcome for mental disorders. A meta-analysis.

Authors:  E C Harris; B Barraclough
Journal:  Br J Psychiatry       Date:  1997-03       Impact factor: 9.319

3.  Critical periods of suicide risk in Huntington's disease.

Authors:  Jane S Paulsen; Karin Ferneyhough Hoth; Carissa Nehl; Laura Stierman
Journal:  Am J Psychiatry       Date:  2005-04       Impact factor: 18.112

4.  Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation.

Authors:  J R Campodonico; A M Codori; J Brandt
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-12       Impact factor: 10.154

5.  Relationships of age and axis I diagnoses in victims of completed suicide: a psychological autopsy study.

Authors:  Y Conwell; P R Duberstein; C Cox; J H Herrmann; N T Forbes; E D Caine
Journal:  Am J Psychiatry       Date:  1996-08       Impact factor: 18.112

6.  Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum.

Authors:  R J Ferrante; C A Gutekunst; F Persichetti; S M McNeil; N W Kowall; J F Gusella; M E MacDonald; M F Beal; S M Hersch
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

7.  Symptom profile, Axis II comorbidity and suicidal behaviour in young males with DSM-III-R depressive illnesses.

Authors:  G Spalletta; A Troisi; M Saracco; N Ciani; A Pasini
Journal:  J Affect Disord       Date:  1996-07-08       Impact factor: 4.839

Review 8.  The epidemiology of Huntington's disease.

Authors:  P S Harper
Journal:  Hum Genet       Date:  1992-06       Impact factor: 4.132

9.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

10.  Correlates of early disability in Huntington's disease.

Authors:  R Mayeux; Y Stern; A Herman; L Greenbaum; S Fahn
Journal:  Ann Neurol       Date:  1986-12       Impact factor: 10.422

View more
  17 in total

Review 1.  Therapy in Huntington's disease: where are we?

Authors:  Martha A Nance
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

2.  Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Authors:  Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready
Journal:  J Huntingtons Dis       Date:  2019

3.  PSYCHIATRIC DISORDERS ASSOCIATED WITH FXTAS.

Authors:  Andreea L Seritan; Melina Ortigas; Stefan Seritan; James A Bourgeois; Randi J Hagerman
Journal:  Curr Psychiatry Rev       Date:  2013

4.  Suicidal Ideation Assessment in Individuals with Premanifest and Manifest Huntington Disease.

Authors:  Melissa Wesson; Nicholas R Boileau; Joel S Perlmutter; Jane S Paulsen; Stacey K Barton; Michael K McCormack; Noelle E Carlozzi
Journal:  J Huntingtons Dis       Date:  2018

5.  Viral vector mediated expression of mutant huntingtin in the dorsal raphe produces disease-related neuropathology but not depressive-like behaviors in wildtype mice.

Authors:  Mark Pitzer; Jordan Lueras; Anna Warden; Sydney Weber; Jodi McBride
Journal:  Brain Res       Date:  2015-02-28       Impact factor: 3.252

Review 6.  Huntington's Disease-Update on Treatments.

Authors:  Kara J Wyant; Andrew J Ridder; Praveen Dayalu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

Review 7.  Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience.

Authors:  Caroline Ménard; Madeline L Pfau; Georgia E Hodes; Scott J Russo
Journal:  Neuropsychopharmacology       Date:  2016-06-13       Impact factor: 7.853

8.  Depression in the early stages of Huntington disease.

Authors:  Eric A Epping; Jane S Paulsen
Journal:  Neurodegener Dis Manag       Date:  2011-10-01

Review 9.  Risk factors of suicidal ideation in Huntington's disease: literature review and data from Enroll-HD.

Authors:  Philipp Honrath; Imis Dogan; Olga Wudarczyk; Katharina S Görlich; Mikhail Votinov; Cornelius J Werner; Beate Schumann; Rena T Overbeck; Jörg B Schulz; Bernhard G Landwehrmeyer; Raquel E Gur; Ute Habel; Kathrin Reetz
Journal:  J Neurol       Date:  2018-08-27       Impact factor: 4.849

10.  Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial.

Authors:  Andrew McGarry; Michael P McDermott; Karl Kieburtz; Wai Lun Alan Fung; Elizabeth McCusker; Jing Peng; Elisabeth A de Blieck; Merit Cudkowicz
Journal:  Neurology       Date:  2019-03-08       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.